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N-acetyl glutamic acidAminoacylase 1 is a zinc-binding enzyme which hydrolyzes N-acetyl amino acids into the free amino acid and
acetic acid. Deﬁciency of aminoacylase 1 due to mutations in the aminoacylase 1 (ACY1) gene follows an
autosomal-recessive trait of inheritance and is characterized by accumulation of N-acetyl amino acids in the
urine. In affected individuals neurological ﬁndings such as febrile seizures, delay of psychomotor
development and moderate mental retardation have been reported. Except for one missense mutation
which has been studied in Escherichia coli, mutations underlying aminoacylase 1 deﬁciency have not been
characterized so far. This has prompted us to approach expression studies of all mutations known to occur in
aminoacylase 1 deﬁcient individuals in a human cell line (HEK293), thus providing the authentic human
machinery for posttranslational modiﬁcations. Mutations were inserted using site directed mutagenesis and
aminoacylase 1 enzyme activity was assessed in cells overexpressing aminoacylase 1, usingmainly the natural
high afﬁnity substrate N-acetyl methionine. Overexpression of the wild type enzyme in HEK293 cells resulted
in an approximately 50-fold increase of the aminoacylase 1 activity of homogenized cells. Most mutations
resulted in a nearly complete loss of enzyme function. Notably, the two newly discovered mutations p.
Arg378Trp, p.Arg378Gln and the mutation p.Arg393His yielded considerable residual activity of the
enzyme, which is tentatively explained by their intramolecular localization and molecular characteristics.
In contrast to aminoacylase 1 variants which showed no detectable aminoacylase 1 activity, aminoacylase 1
proteins with the mutations p.Arg378Trp, p.Arg378Gln and p.Arg393His were also detected inWestern blot
analysis. Investigations of the molecular bases of additional cases of aminoacylase 1 deﬁciency contribute to
a better understanding of this inborn error of metabolism whose clinical signiﬁcance and long-term
consequences remain to be elucidated.ie und Stoffwechsel, Zentrum
eiburg, Mathildenstr. 1, 79106
61 270 4527.
de (J.O. Sass).
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N-acylation of a protein usually leads to extension of its half life.
A total of 50%–80% of all cellular proteins show formylated or
acetylated N-termini [1]. Following the degradation of proteins, free
amino acids can be recycled by enzymatic hydrolysis of N-acylated
amino acids catalyzed by aminoacylases [2,3]. Aminoacylases are
evolutionary conserved cytosolic zinc-bindingmetalloenzymes which
belong to the M20 family [4,5].
Aminoacylase 2, also known as aspartoacylase (ASPA; EC 3.5.1.15)
hydrolyzes speciﬁcally N-acetyl-L-aspartate. ASPA deﬁciency causes
spongy degeneration of the brain known as Canavan disease [6].Canavan disease is a leukodystrophy leading to severe impairment
and, reportedly, often to death in early childhood [7]. Patients show
increased urinary levels of N-acetylaspartic acid.
In contrast to aminoacylase 2, aminoacylase 1 (ACY1; EC 3.5.1.14)
(encoded by the ACY1 gene) has a wide substrate speciﬁcity,
comprising many N-acylated amino acids [8,9]. In agreement with
this, genetic deﬁciency of ACY1 has recently been discovered in
several children with accumulation of N-acetylated amino acids in
urine. They were identiﬁed by organic acid analysis in urine, which is
part of the diagnostic procedure if an inborn error of metabolism is
suspected [10,11]. ACY1 is highly expressed in human kidney and
brain. The majority of patients reported so far as being affected by
ACY1 deﬁciency presented with neurological features like psycho-
motor delay or febrile seizures [10,11]. ACY1 deﬁciency has also been
described in a patient with autistic behavior [12]. All patients with a
characteristic pattern of urinary metabolites showed strongly de-
creased activity of ACY1 in lymphocytes/ﬁbroblasts and presented
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the coding region of the ACY1 gene could be identiﬁed by mutation
analysis [10,11,13]. However, expression analyses of mutated ACY1
enzyme have not been performed so far with the exception of a single
missense mutation (c.1057CNT, p.Arg353Cys), which has been
studied in Escherichia coli [11].
Pittelkow et al. have suggested that porcine ACY1 (pACY1) protein
has two glycosylation sites, although the presence of carbohydrates in
the puriﬁed enzyme has not been demonstrated yet [14]. pACY1
presents with acetylation as a postranslational modiﬁcation of the
alanine residue following the starter methionine [15]. The protein
sequences of human ACY1 and pACY1 show 85% homology [5], but
posttranslational glycosylation patterns have not been investigated
for human ACY1 so far. The human ACY1 protein shows one possible
glycosylation site in the peptide dimerization domain (Asn-Lys-Thr)
and two glycosylation sites in the C-terminal peptidase domain (Asn-
Lys-Thr; Asn-Arg-Thr), respectively [16]. Since human ACY1 reference
protein has not been crystallized yet, assumptions on its structure are
largely based on information on the porcine enzyme, on a crystallized
human ACY1 T347G mutant and on the high percentage of homology
of human and pig ACY1 [5,17,18].
In view of possible posttranslational modiﬁcations of ACY1, which
could be lost in a different expression system, characterization of
the previously reported mutations was now approached using a
mammalian system. Here, we report expression studies in a human
cell line (HEK293) of all ﬁve known mutations identiﬁed in ACY1
deﬁcient individuals, thus providing the authentic machinery for
posttranslational modiﬁcations. In addition, three newly diagnosed
patients with ACY1 deﬁciency are described, whose ACY1 mutations
are included in the expression studies.
2. Patients, material and methods
2.1. Patients
For most mutations studied here, patients with ACY1 deﬁciency
have been reported previously [10–13]. However, case descriptions of
three newly identiﬁed individuals expand both the clinical picture
and the information on mutations in ACY1.
AC007 II-1 is the ﬁrst child of reportedly non-consanguineous
parents originating from Liberia. Following several episodes of febrile
seizures the boy presented at 4.5 years with severe mental retarda-
tion, autistic features and lack of speech development. When he was
6 years and 9 months old, cerebral imaging revealed bihemispheric,
frontally accentuated, cortical dysplasia with gray matter heterotopia.
AC014 II-1 is the ﬁfth child of consanguineous parents originating
from the Lebanon. The girl presented with psychomotor retardation
(startedwalking at 2.5 years, only fewword of active speech at 3 years).
Her siblings are healthy.
AC013 II-1, the seven-year-old daughter of consanguineous Turkish
patients, presented with mental retardation, short stature (1st
percentile) and adiposity (body-mass index 93rd percentile). Metabolic
studies were initiated after the patient had complained because of pain
in her left hip.
All three individuals were identiﬁed by the assessment of urinary
organic acids which is routinely performed as part of a metabolic
work-up if an inborn error of metabolism is considered.
2.2. Mutation analysis
GenomicDNAwas extracted directly fromperipheral blood or from
Epstein–Barr virus (EBV) transformed lymphocytes using by standard
methods. Mutation analysis followed essentially the description by
Sass et al. (2006) [10].
Some primers were redesigned using Primer3 software (http://
frodo.wi.mit.edu/primer3) and were purchased from Euroﬁns MWG/OPERON. All exons and exon–intron boundaries of the ACY1 gene
from patient DNA samples were ampliﬁed by PCR and prepared
for bidirectional sequencing by a commercial provider (LGC Genomics,
Berlin, Germany). DNA sequences were analyzed using BioEdit
software (http://www.mbio.ncsu.edu/bioedit/bioedit.html).
2.3. Restriction fragment length analysis
Inorder to screen for themutation c.1156CNT (p.Arg386Cys) in exon
15 of the ACY1 gene, a 600 bp PCR product was ampliﬁed using primers
Ex15_RV_F (5′-CTGCCACTGACAACCGCTAT-3′) and Ex15_RV_R (5′-
GGTGGCCACTCAAATACCAA-3′), followed by a restriction digest using
BtgI (New England Biolabs) at 37 °C, 20 h. DNA fragment size was
veriﬁed by agarose gel electrophoresis. For comparison, in addition to
samples of ACY1 deﬁcient patients and their parents, samples of 105
control individuals were studied who usually originate from South-
western Germany.
2.4. Cloning and site-directed mutagenesis
A pOTB7 ACY1 cDNA clone (MGC-2251) carrying chloramphenicol
resistance and the gene for human ACY1 was purchased from the
American Type Culture collection (ATCC). The human ACY1 cDNA
consists of 1415 base pairs (bp) with 61 bp and 188 bp untranslated
sequence at the 5′ and the 3′ end, respectively. The ACY1 cDNA
sequence was cloned from the pOTB7 ACY1 cDNA clone into the
mammalian expression vector pcDNA3.1/+ (Invitrogen) by using the
restriction sites EcoRI and XhoI. The pcDNA3.1/+ plasmid provides
ampicillin resistance for selection. The restriction digest with EcoRI
and XhoI was carried out at 37 °C, 2 h. Subsequently, the endonu-
cleases were inactivated by heating the reaction mix at 80 °C, 20 min,
followed by gel extraction using QIAquick Gel Extraction Kit
(Qiagen). Successful cloning was veriﬁed by colony PCR using the
primers pcDNA3.1+_F 5′-CGGTGGGAGGTCTATATAAGCA-3′ and
pcDNA3.1+_R 5′-TTAGGAAAGGACAGTGGGAGTG-3′.
All six mutations in the ACY1 gene which have been reported
previously [10,11,13] as well as two novel mutations were inserted
into the pcDNA3.1/+ ACY1 cDNA clone using the Stratagene
QuickChange Site-Directed Mutagenesis Kit. Mutagenesis primers
were designed using QuickChange Tm calculator (https://www.
genomics.agilent.com/). Plasmid DNAwas prepared using Qiagen kits.
2.5. Cell culture and transfection
Expression studies for ACY1 were performed in HEK293 cells,
transformed human embryonic kidney cells. HEK293 cells were
purchased from DSMZ (Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH, Braunschweig, Germany) and subcultured in
DMEM (Dulbecco's Modiﬁed Eagle's Medium) from Gibco supple-
mented with 10% heat-inactivated fetal bovine serum, 100 U/ml
penicillin G (sodium salt), 100 μg/ml streptomycin sulfate and 25 μg/ml
amphotericin B (Gibco). Transfections of 10 μg plasmid DNA (including
mutants and controls) into HEK293 cells were carried out using
Xfect transfection reagent (Clontech) according to manufacturer's
instructions.
2.6. ACY1 enzyme activity
ACY1 enzyme activity was assessed in homogenized EBV-
transformed lymphocytes and HEK293 cells using on a ninhydrin-
based photometric assay described by Mitz and Schlueter (1958),
which was adapted to cell homogenate probes and to a microscale
reaction [19]. Substrate N-acetyl-L-methionine was used at a ﬁnal
concentration of 2 mM, substrate N-acetyl-L-glutamate was used at
100 mM. The absorption of the reaction products of released amino
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Fig. 1. Assessment of ACY1 activities in HEK293 cells revealed loss of enzyme activity
with missense mutations ACY1 Arg197Trp, ACY1 Glu233Asp, ACY1 Arg353Cys, ACY1
Arg386Cys andwith frame shift mutation ACY1 Pro369fsX46. Mutants ACY1 Arg378Trp,
ACY1 Arg378Gln and ACY1 Arg393His showed not more than a slight decrease in ACY1
activity, if compared to HEK293 cells expressing ACY1WT. (HEK293−: non-transfected
cells; pcDNA3.1/+: mock control, HEK293 cells transfected with the empty vector).
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(BIOTEK). Gen5 1.6 software was used for data evaluation.
2.7. SDS–PAGE and Western blot analysis
ACY1 expression was studied on the protein level by SDS–PAGE
followed by Western blot analysis. The protein concentrations of the
samples were determined by the Lowry method using bovine serum
albumin as the standard [20]. The Precision Plus Protein™ standard
(BIORAD) was used to estimate the protein sizes. Proteins were
transferred onto a polyvinylidenﬂuoride membrane using a Trans-
Blot® semi dry blot system (BIORAD). Anti-ACY1 antibody produced
with a peptide consisting of amino acids 89–336 of human ACY1 was
used at a dilution of 1:1000 (GeneTex, Inc.; GTX110348). The
secondary antibody (goat anti-rabbit IgM+IgG) was obtained from
Southern Biotech (4010–05) and used at a dilution of 1:8000. The
comparison of the intensities of the different ACY1 wild type (WT)
and ACY1 mutant protein bands was performed using the ImageJ
(http://rsbweb.nih.gov/ij/) software program. The intensity of the
ACY1 WT protein band was set to 100%.
3. Results
3.1. Patients
All patients studied presented with abnormal patterns of urinary
organic acids as assessed by gas chromatography–mass spectrometry.
Notably, in the three newly identiﬁed patients abnormalities in the
metabolite pattern (accumulation of N-acetylated amino acids) were
much less pronounced than in previously reported patients. While N-
acetyl-L-glutamate remained detectable in the urine (except for one
organic acid pattern of patient AC014 II-1, which was considered
completely normal), N-acetyl-L-methionine, previously considered
another sensitive marker for ACY1 deﬁciency, was not detectable in
the urine samples of these children.
3.2. Mutation analysis
Two novel point mutations (c.1133GNA [p.Arg378Gln]; c.1132CNT
[p.Arg378Trp]) were identiﬁed in exon 15 of the ACY1 gene of patients
AC013 II-1 and AC014 II-1, respectively. Patient AC007 II-1 showed
a single point mutation at the nucleotide position 1156 of the
ACY1 gene (c.1156CNT [p.Arg386Cys]) (Table 1). Our results suggest
homozygosity for the speciﬁc mutations in all three cases. Full
sequencing of the coding region of ACY1 revealed no further deviation
from the reference sequence. For patient AC014 II-1, the assumption
of homozygosity was supported by the detection of heterozygosity for
the speciﬁc ACY1 mutation c.1132CNT (p.Arg378Trp) in the DNA of
the parents. No DNA of the parents of patients AC007 II-1 and AC013
II-1 was available for analysis, but in view of known consanguinity orTable 1
Aminoacylase 1 (ACY1) activities in homogenates prepared from EBV-transformed patient
determined.
Mutation (DNA) Mutation (protein) Mean ACY1 en
(in lymphocyt
N-Acetyl-L-me
[μmol×g−1×
positive control - - 0.00
AC007 II-1 homozygous c.1156CNT p.Arg386Cys 0.22
AC013 II-1 homozygous c.1133GNA p.Arg378Gln 0.99
AC014 II-1 homozygous c.1132CNT p.Arg378Trp 0.32
negative controls:
A – – 1.85
B – – 1.40
C – – 2.16at least a common geographical background of the parents homozy-
gosity appears plausible in those cases as well, although it was not
formally proven.
3.3. Expression studies and Western blot analysis
The ACY1 wild type (WT) protein was expressed in HEK293 cells
and yielded approximately 50-fold higher ACY1 enzyme activity in
cell homogenates than cells transfected with the pcDNA3.1/+ mock
vector.
In contrast, the mutants ACY1 Arg197Trp, ACY1 Glu233Asp, ACY1
Arg353Cys, ACY1 Pro369fsX46, ACY1 Arg386Cys displayed a loss in
enzyme activity compared to overexpressed ACY1 WT enzyme.
Recombinants ACY1Arg378Trp, ACY1Arg378Gln andACY1Arg393His
showed major residual enzyme activity (Fig. 1), whereas the ACY1
Arg378Gln and ACY1 Arg393His mutants yielded the same enzyme
activity level as the ACY1 WT enzyme. ACY1 Arg378Trp showed
50% residual enzyme activity of ACY1 WT. ACY1 protein expression
in HEK293 cells was analyzed using Western blot analysis. The
housekeeping enzyme glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) served as a positive loading control in Western blot analysis
(Fig. 2). Enzyme activity data are well in agreement with the results
of Western blot analysis using an antibody against human ACY1. Nolymphocytes. Mean values are calculated from at least n=3 experiments. n.d.=not
zyme activity
es, substrate:
thionine)
min−1]
Standard deviation Mean ACY1 enzyme activity
(in lymphocytes, substrate:
N-Acetyl-L-glutamate)
[μmol×g−1×min−1]
Standard
deviation
0.01 0.02 0.03
0.14 n.d. n.d.
0.41 0.69 0.13
0.01 0.08 0.09
0.87 0.67 0.26
0.53 0.97 0.22
0.85 0.79 0.32
Fig. 2. Western blot analysis of ACY1 protein (molecular weight of the mono-
mer=46 kDa). Use of GAPDH as the control demonstrates comparable loading of all
lanes. Based on 100% intensity for ACY1 WT protein overexpressed in HEK293 cells,
relative intensities were determined for variants ACY1 Arg378Trp (40% intensity), ACY1
Arg378Gln (66% intensity) and ACY1 Arg393His (243% intensity). No ACY1 protein was
detected with mutants ACY1 Arg353Cys, ACY1 Arg197Trp, ACY1 Glu233Asp, ACY1
Arg386Cys and ACY1 Pro369fsX46.
688 A. Sommer et al. / Biochimica et Biophysica Acta 1812 (2011) 685–690protein band corresponding to ACY1 was detected in transfected cells
carrying ACY1 mutants, which resulted in no measurable enzyme
activity. In contrast, strong ACY1 signals were obtained in theWestern
blot analysis not only for the ACY1 WT enzyme but also for ACY1
Arg393His. A considerable amount of ACY1 protein, although less
than for ACY1 WT, was also detected for ACY1 Arg378Trp and ACY1
Arg378Gln.Fig. 3.Map of the restriction digest using BtgI (Primer F—forward primer; Primer R—reverse
site. DNA samples of heterozygous individuals yielded three bands of 206 bp, 400 bp and 6
negative control lacks the c.1156CNT mutation, thus yielding a double-band pattern (400 b3.4. Restriction fragment length analysis of c.1156CNT (p.Arg386Cys) in
ACY1
Biallelic loss of the BtgI restriction site, comprising nucleotide 1156
of the ACY1 coding sequence, results in a single DNA band of 606 bp.
Heterozygosity for the mutation c.1156CNT (p.Arg386Cys) or another
sequence variation in the ACY1 gene, which disrupts the BtgI
restriction site, results in three bands of 206 bp, 400 bp and 606 bp.
A total of 105 reference samples corresponding to 210 chromosomes
all yielded bands of 206 and 400 bp only, revealing a functional BtgI
restriction site and therefore no evidence for the mutation c.1156CNT
(Fig. 3).
4. Discussion
Transient overexpression of ACY1 WT protein in HEK293 cells
resulted not only in strong protein bands reacting with the anti-ACY1
antibody in Western blot analysis but also in high enzyme activity.
This suggests that the human cell expression system chosen here
fulﬁlls the requirements for the synthesis of a correctly folded, active
protein.
In contrast to the ACY1 WT protein, overexpression of mutants
ACY1 Arg197Trp and ACY1 Glu233Asp yielded no detectable ACY1
activity. This is in agreement with the results of enzyme activity tests
in corresponding patient cells and has been ascribed to the
localization of the mutations in the highly evolutionary conserved
and functionally relevant ACY1 protein dimerization domain [10,13].
The zinc-binding site is situated in the center of the ACY1
dimerization domain (Fig. 4) [18]. Even though both amino acid
residues are localized contrary to the zinc binding dimerization and
catalytic site, mutations p.Arg197Trp and p.Gln233Asp result in non-
functional ACY1 protein. Moieties of both the amino acids 197 and 233
are oriented towards the secondmonomer and thus may play a role in
stabilization of the homodimeric structure (Fig. 4).
In contrast, the exchange of Arg353 with Cys (p.Arg353Cys)
probably disrupts the globular catalytic subunit [11]. It is likely that
impaired interactions of the His373 residue with the Zn1 ion of
the catalytic site result not only directly in loss of enzyme activity
but yields also in an unstable dimeric protein structure prone toprimer) Point mutation c.1156CNT (p.Arg386Cys) results in loss of the BtgI restriction
06 bp on a 1% agarose gel. Samples of patients displayed only one band of 606 bp. The
p and 206 bp).
Fig. 4. ACY1 T347G mutant homodimeric protein structure (structure is available at: http://www.rcsb.org/pdb/explore/explore.do?structureId=1Q7L) [21]: One monomer of the
structure is colored in gray and the other one in black. The zinc ions are labeled blue and their interacting amino acid residues are marked in orange. Amino acids (Arg197, Arg353,
Pro369, Arg378, Arg386 and Arg393) which were alternatively replaced by our approach using site-directed mutagenesis in the ACY1 gene are colored in purple and labeled in one of
the monomers.
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in control populations, both by Van Coster et al. (2005) and by Sass
et al. (2006) [10,11]. Although not indicated as a single nucleotide
polymorphism (SNP) in the SNP database (NCBI SNP database; http://
www.ncbi.nlm.nih.gov/projects/SNP), it is likely that it represents a
polymorphism affecting ACY1 activity.
The frame shift mutation c.1105_1106insAC (p.Pro369fsX46) even
results in loss of the catalytically important amino acid His373 and
hence results in loss of ACY1 enzyme functions. The insertion suggests
an altered DNA sequence resulting in loss of the original stop codon
and major elongation of the translation product making it prone to
early degradation.
While some residual activity was still observed in lymphocyte
homogenate of patient AC007 II-1, who is homozygous for the
mutation p.Arg386Cys, transient overexpression of the mutation in
HEK293 cells resulted in complete loss of ACY1 activity. The latter
can be explained by perturbation of an alpha-helix structure in the
C-terminal peptidase domain (Fig. 4). This sequence variation has
been reported as a SNP in the NCBI SNP database, occurring e.g., in
individuals from Nigeria. However, we did not observe p.Arg386Cys
in any of 105 control samples collected in Southwestern Germany.
It is in agreement with a profound loss of protein stability/early
protein degradation that all ﬁve mutations listed above did not only
result in completely abolished enzyme activity but also in loss of
immunoreactive ACY1 protein.
This is in sharp contrast to both studiedmutations affectingArg378.
Mutations p.Arg378Trp and p.Arg378Gln resulted not only in ACY1
protein detectable by Western blot analysis but also in major residual
enzyme activity. Arg378 is present in the C-terminal peptidase domain
but is oriented away from the catalytic site and its zinc-binding center.It is expected that the replacement of arginine with tryptophan has a
higher impact on the protein secondary structure compared to an
exchange with glutamine because tryptophan is an aromatic amino
acid. Tryptophanwould occupymore space in the structure and its side
chain may interact with the proline369 in an adjacent loop structure
(Fig. 4) which could result in a change of catalysis. Arginine and
glutamine are both basic amino acids and their side chains are
structurally alike, whereas tryptophan is a lipophilic, aromatic amino
acid and may change the characteristics of this protein region much
more than an exchange with glutamine. This is well reﬂected by
the lower enzyme activity of ACY1 Arg378Trp compared to ACY1
Arg378Gln. High residual ACY1 activities of lymphocytes of patients
AC013 II-1 and AC014 II-1, which are homozygous for the mutations
p.Arg378Gln and p.Arg378Trp in the ACY1 gene, corroborate the results
obtained with the overexpressed mutated protein. Although abnor-
malities in the pattern of urinary organic acids were less pronounced
for these two patients than is usually observed in ACY1 deﬁciency, it
still pointed to this diagnosis. Since there was almost no increase in
urinary N-acetyl-L-methionine, it was speculated that the mutations
p.Arg378Trp and p.Arg378Gln may have modiﬁed substrate speciﬁcity,
keeping hydrolysis of N-acetyl-L-methionine possible. Therefore, the
enzyme activity assay was also performed with N-acetyl-L-glutamate,
one of the alternative substrates indeed identiﬁed in these patients'
urine samples. However, this yielded no preference of the enzyme
variants of patients AC013 II-1 and AC014 II-1, if compared to the use of
the standard substrate N-acetyl-L-methionine and to reference samples.
The mutation p.Arg393His affects an amino acid residue beyond
the C-terminal peptidase domain of ACY1, which most likely does not
interact with the catalytic center and amino acid His373 (Fig. 4). This
is compatible with the unaffected enzyme activity of overexpressed
690 A. Sommer et al. / Biochimica et Biophysica Acta 1812 (2011) 685–690ACY1 Arg393His and with the strong signal of the mutated protein in
Western blot analysis, which resembles that of the WT protein.
However, preservation of ACY1 activity does not necessarily mean
that a mutation such as p.Arg393His plays no biological role. Maceyka
et al. (2004) have shown that ACY1 protein can interact with the
sphingosine kinase type 1 (SphK1). This suggests functions of ACY1 in
regulating other proteins such as SphK1, which, for instance, is known
to promote cell growth and inhibit apoptosis of tumor cells [21,22].
Notably, seven of the mutations which we have identiﬁed in
the ACY1 gene affect primarily the peptidase dimerization domain, the
C-terminal peptidase domain or an even subsequent part of the
protein. No patient has been identiﬁed so far with mutations affecting
the N-terminus of the ACY1 protein. It is remarkable that Maceyka
et al. have demonstrated that a recombinant ACY1 variant lacking the
ﬁrst 231 amino acids can also bind SphK1 [21]. However, this variant
protein has distinct consequences if compared with interactions of
full-lengths ACY1 with SphK1. The shorter variant inactivates SphK1
thus resulting in decreased proliferation and enhanced apoptosis in
tumor cells [21]. Hence, one may speculate that the N-terminal region
of the ACY1 gene is rather conserved since its integrity may be crucial
for the quality of the effects of ACY1 on SphK1 or other regulatory
mechanisms. As mentioned before [13], a role of ACY1 as a potential
modiﬁer could explain the phenotypic variability observed in ACY1-
deﬁcient individuals.
Our data show that the HEK293 cell system is suitable for
expressing human ACY1 proteins. Expression analysis conﬁrmed the
causal relation between mutations in the ACY1 gene, ACY1 activity
and metabolite patterns. Ongoing research in our laboratory is aiming
at a better understanding of possible regulatory functions of ACY1.
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